Hepatorenal syndrome
Functional renal failure in cirrhosis · GI / Surgical
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
In advanced liver disease, splanchnic vasodilation reduces effective renal perfusion, causing progressive AKI without intrinsic renal pathology. Volume challenge with albumin, vasoconstrictors (terlipressin) and treating precipitants are key while planning definitive care.
Assessment
Investigations
- U&E/creatinine trend, urine sodium (low)
- Exclude hypovolaemia, sepsis, nephrotoxins, obstruction
- Ascitic tap to exclude SBP
- Liver screen
Management
- Stop diuretics and nephrotoxins; treat infection
- Volume expansion with IV albumin (diagnostic and therapeutic)
- Vasoconstrictor - terlipressin (or noradrenaline in HDU) with albumin
- Treat precipitants (SBP, bleeding)
- Hepatology; consider transplant assessment
Drugs & doses
IV albumin 20%
Terlipressin
Empirical antibiotics per BNF — see the in-app Antibiotic Dosing tool
Disposition
Hepatology/HDU.
Diagnose hepatorenal syndrome only after a proper albumin challenge has failed and other causes of AKI are excluded. Antibiotic doses per BNF (current edition); confirm choice in the in-app Antibiotic Dosing tool.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.